Market Cap (In TWD)
31.79 Billion
Revenue (In TWD)
56.91 Million
Net Income (In TWD)
-238.04 Million
Avg. Volume
844.91 Thousand
- Currency
- TWD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 65.6-400.0
- PE
- -
- EPS
- -
- Beta Value
- 0.357
- ISIN
- TW0006535008
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Li Fang Pan
- Employee Count
- -
- Website
- https://www.lumosa.com.tw
- Ipo Date
- 2015-07-16
- Details
- Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
More Stocks
-
AU
-
9302
-
AZS
-
6787
-
VRPX
-
PNBK
-
000066
-
RAFI